Cetuximab plus FOLFIRI: Final data from the CRYSTAL study on the association of KRAS and BRAF biomarker status with treatment outcome

被引：16

作者：

Van Cutsem, E.

Lang, I.

Folprecht, G.

Nowacki, M.

Barone, C.

Shchepotin, I.

Maurel, J.

Cunningham, D.

Celik, I.

Kohne, C.

机构：

[1] Univ Hosp Gasthuisberg, Dept Digest Oncol, B-3000 Louvain, Belgium

[2] Natl Inst Oncol, Budapest, Hungary

[3] Univ Hosp Carl Gustav Carus, Dresden, Germany

[4] Maria Sklodowska Curie Mem Canc Ctr, Warsaw, Poland

[5] Univ Cattolica Sacro Cuore, I-00168 Rome, Italy

[6] Natl Canc Inst, Kiev, Ukraine

[7] Hosp Clin Barcelona, Barcelona, Spain

[8] Royal Marsden NHS Fdn Trust, London, England

[9] Merck KGaA, Darmstadt, Germany

[10] Onkol Klinikum Oldenburg, Oldenburg, Germany

来源：

关键词：

D O I：

10.1200/jco.2010.28.15_suppl.3570

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

3570

引用

页数：2